Fundamental Data for KNSY

Kensey Nash Corporation designs, develops, manufactures, and processesproprietary biomaterials products for the orthopedics, cardiology,drug/biologics delivery and wound care markets. The company also is involved with cardiovascular medical technology, specifically, arterial revascularization and puncture closure devices. The company intends to leverage its proprietary knowledge and expertise to develop new products and technologies and to explore additional applications for its products.

# Employees: 302

Address: 735 Pennsylvania Drive,Exton,PA,USA

Phone: 484 713-2100

Fax: 484 713-2900

Website: www.kenseynash.com

Email: info@kenseynash.com

Sector: Medical

Industry: MED PRODUCTS

Executive Officers

Joseph W. Kaufmann (Presi.; C.E.O.; Sec.; Dir.)

John E. Nash P.E (V.P.; New Tech.; Dir.)

Wendy F. Dicicco (C.F.O.)

Douglas G. Evans P.E (C.O.O.; Asst. Sec.; Dir.)

Robert J. Bobb (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 1/27/2010

Mean EPS (Next Qtr): $0.40

Mean EPS (Year): $1.78

Mean Estimate(Long Term): $15.00

P/E Ratio(Based on EPS estimate): 13.070

Number of Estimates: 4

Shares Performance

Period	KNSY	Compare to S&P
YTD	20.04 %	-0.65 %
4 Weeks	-3.72 %	-4.76 %
12 Weeks	-12.14 %	-17.17 %

Shares Information

Analyst Coverage: Y

Avg Volume: 79911

Shares Outstanding: 11M

Market Cap: $0.26B

52 Week High: $29.40

52 Week Low: $15.76

P/E Ratio: 13.710

PEG Ratio: 0.870

Split: On 1/1/1990 KNSY split by factor of 1.050

Earnings Performance

EPS Growth in Last Quarter: 4.88 %

EPS Growth in Last Year: 0.00 %

Sales Growth in Last Quarter: -3.74 %

Sales Growth in Last Quarter: -2.02 %

Financials

Qtr Book Value: $2.02

Cash Flow/Share: $9.87

Change in Payout Ratio: 0.000

Price/Sales: 3.170